The 2023 EPOS/EUFOREA criteria for biologic therapy in chronic rhinosinusitis with nasal polyps is a clinical calculator developed by the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) and the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA). This calculator is specifically designed for patients suffering from chronic rhinosinusitis with nasal polyps (CRSwNP), a chronic inflammatory condition of the nasal and sinus mucosa.

The clinical utility of this calculator is to guide clinicians in determining the appropriateness of biologic therapy for patients with CRSwNP. It takes into account various factors such as the severity of the disease, the patient's response to previous treatments, and the presence of comorbidities like asthma or aspirin-exacerbated respiratory disease. 

The EPOS/EUFOREA criteria should not be used in patients without CRSwNP, or in those with contraindications to biologic therapy. It is also not intended to replace clinical judgment or individualized patient care.

2023 EPOS/EUFOREA criteria for biologic therapy in chronic rhinosinusitis with nasal polyps

# Criteria
 # Entry criteria
A. Bilateral polyps in patients who had endoscopic sinus surgery (except in rare cases unfit for surgery)
# Evidence of type 2 inflammation
B. Tissue eosinophils >= 10/high power field)
C. Blood eosinophils >= 150/mcL
D. Total immunoglobulin E >= 100 UI/mL
# Clinical status
E. Requiring systemic corticosteroids (>= 2 courses per year or low-dose for > 3 months) or contraindications to systemic corticosteroids
F. Significantly impaired quality of life (Sino-Nasal Outcome Test-22 >= 40)
G. Significant loss of smell (anosmic on smell test)
H. Comorbid asthma requiring regular use of inhaled corticosteroids

# Conditions
- A and ((((B or C or D) or (B and C) or (B and D) or (C and D) or (B and C and D)) and E and F) or (((B or C or D) or (B and C) or (B and D) or (C and D) or (B and C and D)) and E and G) or (((B or C or D) or (B and C) or (B and D) or (C and D) or (B and C and D)) and E and H) or (((B or C or D) or (B and C) or (B and D) or (C and D) or (B and C and D)) and F and G) or (((B or C or D) or (B and C) or (B and D) or (C and D) or (B and C and D)) and F and H) or (((B or C or D) or (B and C) or (B and D) or (C and D) or (B and C and D)) and G and H) or (E and F and G) or (E and F and H) or (E and G and H) or (F and G and H) or (((B or C or D) or (B and C) or (B and D) or (C and D) or (B and C and D)) and E and F and G) or (((B or C or D) or (B and C) or (B and D) or (C and D) or (B and C and D)) and E and F and H) or (((B or C or D) or (B and C) or (B and D) or (C and D) or (B and C and D)) and E and G and H) or (((B or C or D) or (B and C) or (B and D) or (C and D) or (B and C and D)) and F and G and H) or (E and F and G and H) or (((B or C or D) or (B and C) or (B and D) or (C and D) or (B and C and D)) and E and G and F and H))
- true